NATCO Pharma Limited (BOM:524816)
861.60
-5.80 (-0.67%)
At close: Aug 29, 2025
NATCO Pharma Revenue
NATCO Pharma had revenue of 13.29B INR in the quarter ending June 30, 2025, a decrease of -2.47%. This brings the company's revenue in the last twelve months to 43.96B, up 1.08% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.30B with 10.68% growth.
Revenue (ttm)
43.96B
Revenue Growth
+1.08%
P/S Ratio
3.51
Revenue / Employee
10.95M
Employees
4,016
Market Cap
154.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 44.30B | 4.28B | 10.68% |
Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,839.41B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,503.84B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
NATCO Pharma News
- 9 days ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 9 days ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 15 days ago - Brokerage recommendations for August 14: Muthoot Finance, Va Tech Wabag, JSPL, VMM, BPCL, Devyani, Apollo Hospitals, HDFC Life, Infosys, Brainbees, United Spirits, Motherson, Jubilant Food, PI Industries, Natco Pharma, ONGC in focus - Business Upturn
- 17 days ago - Natco Pharma board declares interim dividend of Rs 2 per share for FY26 - Business Upturn
- 17 days ago - NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY - Business Upturn
- 5 weeks ago - Natco Pharma gets EIR from USFDA for Hyderabad API facility - Business Upturn
- 5 weeks ago - NATCO Pharma offers to acquire 35.75% stake in South Africa’s Adcock Ingram for Rs 2,000 crore - Business Upturn
- 5 weeks ago - Natco Pharma plans to acquire majority stake in South Africa’s Adcock Holdings: Report - Business Upturn